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Abstract: Chitosan is one of the most used polysaccharides in the design of drug delivery 
strategies for administration of either biomacromolecules or low molecular weight drugs. 
For these purposes, it is frequently used as matrix forming material in both nano and 
micron-sized particles. In addition to its interesting physicochemical and biopharmaceutical 
properties, which include high mucoadhesion and a great capacity to produce drug delivery 
systems, ensuring the biocompatibility of the drug delivery vehicles is a highly relevant 
issue. Nevertheless, this subject is not addressed as frequently as desired and even though 
the application of chitosan carriers has been widely explored, the demonstration of systems 
biocompatibility is still in its infancy. In this review, addressing the biocompatibility of 
chitosan carriers with application in drug delivery is discussed and the methods used 
in vitro and in vivo, exploring the effect of different variables, are described. We further 
provide a discussion on the pros and cons of used methodologies, as well as on the 
difficulties arising from the absence of standardization of procedures.  
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1. Introduction 
Micron- and nanosized particles are sophisticated technologies that were developed to answer 
specific demands in the field of drug delivery, namely addressing the limitations posed by the 
administration of a new generation of low molecular weight drugs and biomacromolecules [1,2]. 
Chitosan and its derivatives in the last two decades have proven to be excellent and safe candidates for 
improving mucosal and trans-mucosal delivery or drugs, mainly due to their mucoadhesive and 
absorption enhancing properties, closely related with the cationic character of the polymer [3–5]. 
Indeed, due to its positive charge, chitosan has the special feature of adhering to mucosal surfaces, 
favoring the interaction of the drug with the mucus layer covering different epithelial surfaces [6–8]. 
The potential of chitosan for trans-mucosal drug delivery has been further strengthened by extensive 
demonstrations of its capacity, both in vitro and in vivo, in transitorily widening tight junctions 
between epithelial cells, thus facilitating the transport of poorly absorbable macromolecules through 
well-organized epithelia barriers [2,5]. This particular behavior governs the different toxicological 
patterns between chitosan and conventional absorption promoters, which are known to cause 
permanent epithelial damage.  
In addition to all these positive features, chitosan has been reported to exhibit other relevant 
properties, including biodegradability and biocompatibility [9–11]. In recognition of all these 
appealing characteristics, chitosan has been indicated as a promising biomaterial for biomedical and 
pharmaceutical, i.e., drug delivery, applications. The characterization of its biocompatibility pattern 
encompasses, therefore, a major issue, as it will drive the process of a future human drug delivery 
application. Whereas many of the technological applications of chitosan did not require regulatory 
approval, the use of chitosan in drug delivery, especially in particulate forms, requires significant 
improvement in documentation regarding the biocompatibility and safety of these products. Despite 
the outstanding reputation that comes with chitosan, it is true that a number of challenges related to 
biocompatibility have yet to be met; and some studies seem to raise some doubts concerning its 
applicability. Additionally, it is often erroneously assumed that the formulation of chitosan as a carrier 
does not have implications on its biocompatibility. 
This review highlights the interest of biocompatibility assessment in the development of chitosan-based 
carriers for mucosal drug delivery. We provide the contextualization of biocompatibility in the field of 
drug delivery, presenting the methods used to assess this property and focusing on their advantages 
and disadvantages. Finally, the difficulties arising from the absence of standardized conditions of 
assessment are also addressed. 
2. Chitosan Application in Drug Delivery 
Chitosan is one of the most popular materials in the field of drug delivery and is, by far, the most 
applied of the natural polymers. Its attractiveness relies on very interesting structural and biological 
properties, which include the cationic character and the solubility in aqueous medium on one side, but 
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most importantly, its characteristic biodegradability and mucoadhesivity on the other [4,6,10,12]. 
These properties are a result of the proper structure of the polysaccharide, which is composed of 
repeating alternated units of N-acetylglucosamine and D-glucosamine, linked by β-(1-4) glycosidic 
bonds [13], as depicted in Figure 1.  
Figure 1. Chitosan structure (n and m assume different ratios) [14].  
 
Chitosan is available in a variety of forms that mainly differ in the molecular weight and degree of 
deacetylation [15,16]. These differences affect important characteristics such as solubility and 
mucoadhesivity [5]. With a pKa of approximately 6.5, chitosan is soluble in acidic solutions owing to 
the protonation of the amino groups composing the polymeric chain at this pH [13,17]. In this regard, 
highly deacetylated chitosan (85%) is readily soluble in solutions of pH up to 6.5, but as the 
deacetylation degree decreases, the solubilization becomes more difficult [18]. With respect to the 
mucoadhesive capacity of the polymer, it is reported to increase with the increase in the deacetylation 
degree, as this provides more positively charged amino groups available for the interaction with 
negatively charged residues of the mucus, namely sialic acid [19,20]. In fact, this explains why the 
greatest part of chitosan applications in drug delivery reports the use of highly deacetylated chitosan, 
as mucoadhesion is responsible for a more prolonged retention in the site of action or absorption. 
Applications of chitosan in the field of drug delivery have been mostly focusing on the production 
of carriers that improve the performance and effectiveness of encapsulated molecules, either 
macromolecules or low molecular weight drugs [12,21–23]. Nano and microparticles, as solid 
continuous matrixes, are the most usual carriers with a chitosan-based composition [4,23,24], but 
nanocapsules have also been reported [19,25]. Importantly, many works report the use of chitosan as a 
coating material, instead of being a part of the matrix of the system [22,26–28], which is a relevant 
recognition of chitosan appealing properties. In this respect, the coating of several different core 
structures has been reported, including solid lipid nanoparticles [26,29], polymeric nano and 
microparticles [28,30–32] and liposomes [33,34]. The clear objective of such an approach is to modify 
the surface properties of the core structure, either to improve the pattern of interaction with 
surrounding structures or to improve the biodegradation profile. 
One of the most relevant properties of chitosan, with particular interest in drug delivery, relies on its 
ability to transiently open epithelial tight junctions. This capacity has been demonstrated on numerous 
occasions, both in the form of a solution and carrier, resulting in the permeation enhancement of 
macromolecules through well-organized epithelia such as the nasal [35,36], intestinal [37–39], 
ocular [40], buccal [41] and pulmonary [42]. Another characteristic of chitosan that increases interest 
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in the polymer, is the flexibility of its molecular structure, which facilitates chemical modifications [43] 
that are performed to further improve several properties such as solubility or mucoadhesion [23,44,45]. 
Two of the most critical features of drug delivery systems concern their biodegradability and 
biocompatibility, which are mandatory requisites for acceptance by the regulatory agencies. 
Biodegradability becomes a crucial feature when considering acute and long-term toxicity, as  
non-degradable materials may accumulate in organs or even intracellularly [10]. Chitosan has been 
reported as highly biodegradable, which is mainly due to the fact that, under physiological conditions, 
its molecular chains can be digested by either lysozyme or chitinase. While the former is reported to 
exist in mucosal surfaces [10,11,46], the latter is produced by normal intestinal flora [11,43]. In 
addition, when oral delivery is under consideration, the hydrolytic activity of the acidic gastric medium 
has to be considered as an extra means of chitosan degradation [11,16].  
However, the ability of a material to be biologically degraded, although positively understood, must also 
be considered from the point of view of the possibility of resulting in toxic degradation products [47]. In 
the case of chitosan, its degradation does not raise any critical concern, as the products of its 
metabolism are oligosaccharides that are either incorporated into glycosaminoglycan and glycoprotein 
metabolic pathways or easily excreted in urine directly [48–50]. Furthermore, evidence has been 
produced in several reports that no issues of accumulation/retention in the body are observed [10]. 
Nevertheless, if a too rapid degradation occurs, it might result in an accumulation of amino sugars, 
inducing an inflammatory response and, hence, affecting chitosan biocompatibility [51,52]. 
All the above mentioned properties of chitosan, from its intrinsic structural properties to the 
demonstrated mucoadhesive and permeation enhancement capacities, as well as biodegradability, 
endow this polymer with valuable potential for drug delivery applications. Altogether, these features 
have been resulting in a tremendously increasing number of publications and patents. The 
biocompatibility pattern of the polymer and its carriers is obviously of utmost importance to complete 
the background of relevant properties and to support the potential of chitosan, and will be addressed 
extensively in the following section. 
3. Biocompatibility of Chitosan Carriers 
As referred to previously, chitosan has been proposed very frequently as a carrier or functional 
excipient (for instance, as permeation enhancer) in the formulation of active compounds to be 
delivered [16]. Its biocompatibility is, thus, a current issue of great significance, although the real 
meaning of the word is many times disregarded. Biocompatibility is frequently addressed as absence of 
toxicity, but these are different concepts referring to different contexts. In a very elucidative review on 
the preclinical safety of polymeric carriers, Gaspar and Duncan clearly indicate that while drug 
molecules should be discussed in terms of toxicity, biomedical materials, which include polymeric 
materials, should be considered for their biocompatibility. From this perspective, and as depicted in 
Figure 2, toxicity refers to the potential harm that may be caused by a material, whereas 
biocompatibility further extends to the detrimental or beneficial effect of the physiological 
environment on the material performance [53].  
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Figure 2. Illustration of the distinction between “biocompatibility” and “toxicity” [53].  
 
This differentiation appears in the sequence of the first clear definition of biocompatibility agreed at 
a consensus conference of the European Society for Biomaterials [54] and the recent reformulation of 
that definition [55]. The first definition, dating from 1987, indicates biocompatibility to be the ability 
of a material to perform with an appropriate host response in a specific situation [54]. As said, this was 
recently re-defined to a more complete concept, as being the ability of a biomaterial to perform its 
desired function with respect to a medical therapy, without eliciting any undesirable local or systemic 
effects in the recipient or beneficiary of that therapy, but generating the most appropriate beneficial 
cellular or tissue response in that specific situation, and optimizing the clinically relevant performance 
of that therapy [55]. This comprehensive definition makes the contextualization of biocompatibility a 
mandatory requisite and addresses the possibility that materials are often required to specifically 
interact with the surrounding environment and in many cases with cell structures, instead of being 
ignored by them. It becomes, therefore, clear, that polymers (as well as polymer-based carriers) cannot 
be described as biocompatible without the proper contextualization of route of administration, 
frequency of administration and dose [53].  
Actually, biocompatibility is both region- and host-dependent, meaning that different responses 
might be obtained when evaluating multiple sites or objectives [56]. In this respect, although when 
studies address these issues, the understanding of materials biocompatibility is hindered by the limited 
knowledge on the biological processes that are involved in material-cells interactions [56,57]. This is 
why several high-throughput technologies are being developed and applied to this end, examining 
global cell-biomaterial interactions in a faster way and addressing important questions such as the 
pathways and networks involved in cell-material interactions [56]. 
Almost all works concerning chitosan application refer to the polymer as a non-toxic, biologically 
compatible material, thus suitable to be used in carrier production in the field of drug delivery. 
However, although works addressing the biocompatibility of chitosan carriers are becoming more 
frequent, usually an incomplete set of assays is performed. In other cases, this question is completely 
disregarded, the authors simply assume polymer biocompatibility and, by affinity, that of the carrier. 
Sometimes this statement is based on chitosan approval by the American Food and Drug 
Administration (FDA) as a wound dressing material [16,21], for instance. It is a fact that chitosan is 
approved for that end and also as a dietary component in several other countries [16]. Nevertheless, 
and in the sequence of the above mentioned issues concerning the intrinsic definition of 
J. Funct. Biomater. 2012, 3     
 
 
620
biocompatibility, chitosan biocompatibility must be addressed in the context of each particular case 
and condition. Accordingly, the FDA and other regulatory agencies do not approve materials in a 
general manner, instead evaluating and approving materials with respect to specific applications. In 
this context, a very important issue that seems to be overlooked on many occasions is that, as happens 
for many other materials, chitosan exists in several different structures and formulated as different 
types of carriers for administration in varied conditions. Each entity must, then, be considered 
separately, requiring specific testing in the particular conditions expected for its administration. 
Still in this context, it is not infrequent to find works on the subject of carrier biocompatibility as 
being solely dependent on that of the material composing its structure. This is an erroneous approach, 
as several parameters, other than the material itself, are recognized mediators of the biocompatibility, 
affecting the carrier behavior and determining its clinical outcome; individual characteristics (age, sex, 
general health), as well as the proper structure of carriers (size, morphology, cristallinity, surface 
characteristics, degradation profile and products) are included in this list [55]. It is well recognized 
now that the physicochemical properties of materials can alter dramatically when formulated as 
specific structures like those of the different carriers, as particular interactions take place and the area 
available for contact with surrounding environments is modified in each case. Therefore, the carriers 
may exhibit new and unique biological properties, thus generating potential different risks as compared 
to the raw materials of the same chemistry [47].  
The formulation of chitosan under the form of a carrier may have implications on its biocompatibility 
and, therefore, it is important to address, and treat differently, both the biocompatibility of chitosan as a 
molecule and as a carrier. As a positively charged molecule, chitosan usually provides a great interaction 
with cell membranes, which are negatively charged (approximately −70 mV) due to ionic interchanges 
between the intracellular and extracellular medium, which are mediated by the Na+/K+ pump [58]. 
Actually, owing to that positive charge, chitosan nanoparticles are often taken up by the cells [59]. When 
chitosan is formulated as a carrier and complexed with a drug, the number of positively charged amino 
groups that remains available is frequently decreased, comparatively. This lower number of charges 
consequently affects its capacity to interact either with cell membranes and the surrounding environment, 
potentially decreasing its uptake and, possibly, potential toxicity. As such, highly deacetylated chitosans 
have a naturally higher propensity for cell interaction, as has been demonstrated [60]. 
As previously mentioned, in parallel with the distinction between different chitosan types and the 
need to address the difference between molecules and carriers, it is of utmost importance that 
biocompatibility is understood as a contextual concept. This means that references to the 
biocompatibility of a carrier should be always accompanied by the intended application [55] or, at 
least, in the case of drug delivery, by the route of administration to be focused.  
As the carrier comes in contact with the host, a sequence of events is expected to take place, 
potentially including carrier–protein interactions, as well as those with other surrounding 
macromolecules, and also the induction of inflammatory and/or immune responses [55,56]. Therefore, 
assessing some of these events might give potential indications on the carrier biocompatibility. Many 
in vitro assays are frequently described to provide the evaluation of carrier biocompatibility, in many 
cases in accordance with ISO 10993 [61–63], which describes the topics of evaluation and testing 
relevant for the biological evaluation of medical devices. This standard indicates varied device 
categories, first dividing them according to the nature of their contact with the body (surface devices, 
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external communicating devices and implants). Chitosan carriers as is the focus of this review are 
included in the category of surface devices. A second division then appears, addressing the contact 
time that is expected for the specific device with the body. The most basic tests considered for an 
initial evaluation refer to cytotoxicity, sensitization and irritation or intracutaneous reactivity. Tests 
should include the evaluation of cellular morphology and membrane integrity, as well as metabolism 
efficiency [61]. If contact time extends beyond 24 hours, acute or sub-acute toxicity must be also 
addressed (or even implantation tests, if applicable) [62]. Genotoxicity studies are also covered in the 
ISO 10993 [63]. The importance of assessing genotoxic effects relies on the fact that materials and 
carriers might not be cytotoxic, but evidence the ability to affect the genetic information of the cells 
they are in contact with, for instance leading to abnormal cell growth [64,65]. The standard also 
specifies that in vitro tests should be repeated several times, not only to ensure the validation of the 
used analytical methods, but also to address variations occurring in cells [61]. Furthermore, it 
designates, in certain conditions, a substitution of animal studies by specifically developed in vitro 
tests and indicates the need to improve animal tests to minimize animal pain and distress [66]. The 
tests performed using cells are generally devoid of ethical issues and are easier to control and 
reproduce, being also less expensive in comparison with studies involving animals [64]. Performing 
the proposed in vitro tests may not determine the final carrier biocompatibility, but will certainly 
comprise an important step towards animal studies and the final clinical trials. Importantly, performing 
this set of in vitro assays permits decreasing in vivo testing, thus complying with the requirements of 
the ISO. 
In the following section, assays described in the literature for biocompatibility evaluation of 
chitosan carriers that are applied in drug delivery are presented. 
3.1. In Vitro Cell Toxicity 
In vitro tests of cell toxicity provide a rough assessment of the ability of cells relevant to a 
determined application to survive in the presence of specific materials or carriers, the latter being the 
subject of the present review. In general, two different protocols are observed, one providing a direct 
contact of the carrier with the cells, and another evaluating the effect of the contact with leachable 
materials (diffusible components, degradation products, etc.), thus considering an indirect cell  
contact [57,67].  
A very wide number of assay techniques can be used to evaluate cytotoxicity. Table 1 describes 
those assays reported for the evaluation of chitosan carriers. Whatever the selected test, the generally 
desired outcome is that cell viability remains close to 100% after contacting with the tested 
material/system. Depending on which cellular characteristics are focused, the assays described to 
evaluate chitosan carriers are mainly divided into metabolic assays and membrane integrity assays. 
While the former assess occurrences of an early stage of cell death, the latter determine the occurrence 
of membrane disruption that is more frequent during the later stage of the process [68]. 
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Table 1. Summary of in vitro cytotoxicity assays described for the evaluation of  
chitosan carriers.  
Assay Theoretical principle Evaluated cellular function 
Tryplan blue Blue dye is excluded by viable cells Cell membrane integrity 
Propidium iodide 
Red dye enters damaged cells and intercalates DNA, 
enhancing dye fluorescence 
Cell membrane integrity 
Lactate 
dehydrogenase 
LDH leaks from damaged cell membrane. Enzyme 
transforms NADH + pyruvate into NAD+ + lactate: 
Direct quantification of NADH at 340 nm 
Tetrazolium reduction to formazan 
Cell membrane integrity 
Neutral red Lysosomal uptake of red dye in live cells Lysosomal membrane integrity 
MTT, MTS, XTT 
Tetrazolium reduction to blue formazan in 
metabolically active cells 
Mitochondrial metabolism 
Alamar blue 
Resazurin reduction to pink resorufin by metabolically 
active cells 
Mitochondrial metabolism 
DNA: deoxyribonucleic acid; LDH: lactate dehydrogenase;  
MTT: 3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide);  
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium);  
NAD: nicotinamide adenine dinucleotide;  
NADH: reduced form of nicotinamide adenine dinucleotide;  
XTT: (2,3-bis-(2-methoxy-4- nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide). 
The cell membrane is a functional barrier, using several mechanisms to control the traffic of 
substances into and out of the cellular structure. A disrupted cell membrane implies cell death and, 
therefore, the assays providing the assessment of cell membrane integrity permit the discernment 
between live and dead cells. The trypan blue assay has been frequently used for this end, relying on the 
exclusion of the dye by viable cells, which possess intact cell membranes, while damaged cells include 
the dye because their membranes are no longer capable of controlling molecular permeation [64,69–71]. 
A viable cell thus exhibits a colorless cytoplasm, whereas a damaged one has a blue cytoplasm that is 
easily identified by microscopic observation, as is evidenced in Figure 3 [64,69,72]. Notwithstanding 
the easiness of the procedure, this assay has been referred as imprecise, leading to an overestimation of 
cell viability [69].  
Propidium iodide, a red dye, is also used to indicate membrane disruption. It is membrane-impermeable 
owing to two positive charges existing in its structure [73], but it enters the cells when membrane 
damage occurs. It has a strong ability to intercalate DNA and registers a strongly enhanced 
fluorescence upon binding to nuclei acids, the fluorescence change being proportional to the number of 
damaged cells [64]. At an excitation of 488 nm, it gives a bright signal easily detected and quantified 
by flow cytometry. One of the problems with this assay is that the intercalation is reversible, so that the 
dye might leak out from cells that were dead before fixation and stain the previously viable cells [73]. 
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Figure 3. Illustration of the result of the Trypan blue exclusion assay on cell culture. Cells 
including trypan blue (dead cells) are stained in blue and marked with arrows. Adapted 
with permission from [74]. 
 
Alternatively, an assay based on the determination of the amount of lactate dehydrogenase (LDH) 
that is leaking through a damaged cell membrane has also been used [70]. This enzyme is present in 
cell cytosol and catalyzes the reaction that transforms NADH + pyruvate into NAD+ + lactate. The 
increase of LDH activity in cell culture medium is proportional to the number of lysed cells. Two 
different protocols can be followed for the quantification of LDH. On one side, NADH can be directly 
quantified by spectrophotometry at 340 nm and its amount used to determine LDH level if the reaction 
starts with known levels of NADH and pyruvate [75]. On the other side, the most common approach 
uses commercial quantification kits based on a colorimetric assay. In these kits, the formation of 
NADH can be measured in a reaction where the tetrazolium salt INT is reduced to formazan, which is 
a colored substance. The amount of formazan is determined directly by spectrophotometry at 490 nm 
and proportionally correlates with the amount of LDH and, consequently, with the number of damaged 
cells [64]. The loss of intracellular LDH and its release into the culture medium is an indicator of 
irreversible cell death due to cell membrane damage [76,77].  
The neutral red assay is one of the most frequently used, but it evaluates lysosomal membrane 
integrity rather than cell membrane integrity [71]. This assay is based on the principle that living cells 
are able to capture the dye, storing it in the lysosomes [64,67]. The efficiency of neutral red retention 
depends both on the pH of the lysosome and its membrane proton pump, which maintains the acid 
environment of the lysosomal compartment. Therefore, lysosomes in unstressed cells are able to retain 
the dye for longer periods and a destabilization of lysosomal membrane results in leaking of neutral 
red to the cytosol, decreasing the amount of dye retained in the cells. Neutral red is quantified by 
spectrophotometry at 540 nm [78].  
Metabolic assays are also of widespread application, generally focusing the mitochondrial 
metabolism. A reduction of cellular metabolic activity is generally accepted as an early indicator of 
cellular damage. The most common assay, among all those evaluating cytotoxicity, belongs to this 
category and is the MTT test (uses the compound 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide), which comprises the production of a dye by cells with active mitochondrial activity. This 
assay specifically evaluates an enzyme function, as the yellow tetrazolium salts are reduced to  
water-insoluble purple-blue formazan crystals by mitochondrial dehydrogenases. These crystals 
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precipitate in the cytosol and are then solubilized after the induction of cellular lysis by a surfactant, 
enabling the absorbance to be read at 540 nm [67,76]. Variants of the assay include the MTS  
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and XTT  
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay, which present the 
advantage of avoiding the solubilization step required in the MTT [64]. In all these assays, a 
dysfunction of mitochondrial activity is used as a sensor of disturbed cell function. A higher 
concentration of the dye relates to a higher amount of metabolically active cells, which is usually 
interpreted as higher cell viability. In some cases, this interpretation should not be as linear as it is 
taken generally, as the contact with a metabolic inhibitor would have the same effect without actually 
causing cell death.  
Alamar blue assay also falls in the category of MTT, using the same oxidation-reduction principle. 
The blue coloured agent contains resazurin that is reduced to pink resorufin by metabolically active 
mitochondria, being then quantified by fluorimetry with excitation at 545 nm and emission at 
590 nm [71,79]. In both MTT (or variants) and Alamar blue assays, the reduction has been believed to 
be mediated solely by mitochondrial enzymes. However, some works have been suggesting that other 
enzymes present in the cytosol and microsomes can have a contribution to the reduction reaction [80,81].  
Chitosan carriers have been frequently tested by means of the above mentioned assays, with a 
predominance of the MTT assay, not only using the original polymer [30,82–84], but also chitosan 
derivatives [85,86]. In some cases, a comparison is performed between chitosan solutions and chitosan 
carriers. In many works, however, the isolated effect of materials composing the matrix of drug 
delivery systems or that of drug-loaded carriers is not tested, the evaluation being performed only on 
empty carriers. In these cases, it is not possible to determine rigorously the systems behavior, because 
a material may not cause cell injury but kill an animal due to its drug release pattern [57] 
When analyzing the available studies reporting the assessment of chitosan carriers’ biocompatibility, 
one easily observes that a huge variety of conditions are applied. Even if focusing specifically on the 
works related with drug delivery, a large number of different cells are used, varied material 
concentrations are applied, considering different contact times. In addition, the intrinsic variations 
provided by chitosan as a polymer cannot be disregarded (chitosan as a base or salt, different salts, 
molecular weight, deacetylation degree, etc.), not to mention that very different carriers are also 
available. To make the subject even more difficult, different assays are used that evaluate distinct 
aspects of cellular toxicity. This obviously translates into a wide range of responses that are practically 
impossible to compare, due to unstandardized conditions of assessment. 
Nevertheless, taking into account the overall information made available by the literature, it seems 
possible to say that the general trend indicates that in many cases chitosan solutions exhibit a certain 
degree of toxicity that is mostly dependent on the dose [60,87]. This confirms a fundamental principle 
of toxicology, first expressed by Paracelsus, saying that “The dose makes the poison”. Apart from 
depending on the dose, toxicity was also conditioned by the polymer characteristics, such as molecular 
weight and degree of deacetylation [60,88], as well as by the pH of the incubation medium and time of 
incubation [89,90]. In turn, it is also observed that when the polymer is used as matrix material of drug 
delivery systems, in most cases there is no overt toxicity in concentrations ranging up to approximately 
1 mg/mL, although higher concentrations have been occasionally referred to not decrease cell viability 
as well [28,30,60,84,91–93]. However, the effect is still governed by the used dose [60,90,94].  
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Figure 4 provides examples of very low toxicity of different chitosan carriers determined using 
metabolic assays. 
Figure 4. (a) Cell viability of chitosan/tripolyphosphate nanoparticles in Calu-3  
cells (bronchial epithelial cells) determined by MTT assay (top graphic); and  
(b) chitosan/carrageenan nanoparticles in L929 cells (fibroblasts) determined by MTS 
assay (bottom graphic) [84,91].  
 
(a) 
 
(b) 
The different behaviors observed between chitosan molecules and carriers might be explained by 
the distinct conformation that molecular chains adopt when formulated as carriers, which does not 
allow the exposure of many of the groups responsible for interaction when in solution. Nevertheless, 
there are also works reporting a similar cytotoxic pattern for both chitosan solutions and particles [60]. 
This discrepancy of results is unfortunately observed in the literature and is attributed to the 
previously referred multitude of assay conditions that are used, not only focusing different structural 
materials and cells, but also in what concerns the general specificities of the assays. In the cases where 
chitosan is combined with other polymers to compose the systems’ matrix, the selected secondary 
polymer naturally affects the overall cytotoxicity of the carrier [95,96].  
Many works also report the use of chitosan as a coating material [28,87,97,98]. These approaches 
can endeavor to achieve different outcomes, from an increased mucoadhesion, an enhancement of the 
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biocompatibility profile by surface modification, or a general improvement in the formulation 
performance. Whatever the objective, the final biocompatibility of the system will obviously depend 
on its total composition. In this regard, it has been generally reported that no important toxicity is 
observed when chitosan is coating a specific core [87,97,99,100] or an improvement of the overall 
toxicity is obtained due to the presence of the polysaccharide [28,96,98].  
One important question that is worth mentioning is that, whatever the selected assay, the samples 
incubated with the cells should be sterile, to avoid cell contamination and a misjudgment of 
cytotoxicity. It is further considered that conducting multiple tests, addressing distinct aspects of 
cellular function, is advantageous to ensure that valid conclusions are drawn, permitting a higher 
confidence on the observations [64]. An example of this strategy is evidenced in Figure 5, in this case 
with an observation of some differences in the quantification of cell viability, which are attributed to 
different sensitivities of the used tests. 
Figure 5. Comparison between the viability of A549 cells after incubation with different 
formulations of chitosan/PLGA nanoparticles (0.9 mg/mL) as determined by MTT and 
ATP assays [101].  
 
3.2. In Vitro Detection of Impaired Cell or Epithelial Function 
Although in some cases a toxic effect can result in cell death, there are many other subtler outcomes that 
do not cause sufficient harm to induce cell death, instead interfering in the normal functions or generating 
cellular irritancy or stress. In this context, several assays permit the monitorization of cell function. The 
assays performed in the ambit of the evaluation of chitosan carriers are described in Table 2.  
The adenosine triphosphate (ATP) assay assesses the functional integrity of cells, as cell injury 
results in a decrease of cytoplasmic ATP. ATP plays an important role in energy exchange in 
biological systems, serving as the principal immediate donor of energy and being present in all 
metabolically active cells, as any specialized function will demand the use of energy. ATP level can be 
determined by a luminescent assay in which an enzyme, luciferase, is used to catalyze the formation of 
light from ATP and luciferin. The emitted light intensity is determined and linearly related with the 
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ATP concentration [101,102]. This assay is much more recent than others and, therefore, its use is not 
widespread. Works reporting its application indicate no alterations in ATP intracellular levels, both 
upon incubation with chitosan solution [103] and chitosan-based (polylactide-co-glycolide/chitosan) 
carriers [101]. This latter example is depicted in Figure 5. 
Table 2. In vitro cell function and genotoxicity assays described for the evaluation of 
chitosan carriers.  
Assay Theoretical principle Evaluated cellular function 
ATP 
Reduction in ATP cytoplasmic level indicates cell injury 
Luciferase catalyses light formation from ATP and 
luciferin. Luminescence observation 
Cell functional integrity 
TER Cellular damage or stress induces TER decrease  Cell barrier integrity 
Comet 
Electrophoresis separation of broken DNA strands which 
form the tail of the comet. DNA staining with dye and 
observation by fluorescence microscopy  
DNA damage 
ATP: adenosine triphosphate; DNA: deoxyribonucleic acid; TER: transepithelial electrical resistance. 
Chitosan carriers are often proposed in the ambit of systemic mucosal delivery of drugs, which 
means that the transported drug is expected to permeate an epithelial barrier and enter the blood 
circulation to be systemically distributed. Drug permeation through the transcellular pathway is 
dependent on several physicochemical properties of the drugs, namely on their lipophilicity. In turn, 
mucosal epithelia are generally characterized by the existence of a tight cell barrier, which evidences 
tight junctions between adjacent cells, so that the free diffusion of molecules by the paracellular route 
is prevented [104–106]. The intensity of the tightness of these junctions can be determined in cell 
cultures by a parameter called transepithelial electrical resistance (TER), which provides a 
measurement of the epithelial barrier properties and integrity [107–109]. TER has been pointed 
frequently as a sensitive marker for cellular damage, indicating sub-lethal toxicity [67,101,110] and 
any alteration in TER suggests a change in the epithelial barrier function [110]. Chitosan is known to 
have the ability to transiently open epithelial tight junctions, permitting an increase of drug permeation 
by acting as an absorption promoter. The mechanism underlying chitosan effect relies on the 
interaction of its protonated amino groups with cell membranes. This interaction produces a reversible 
structural reorganization of junction proteins, encompassing a specific redistribution of cytoskeletal  
F-actin and the tight junction protein ZO-1, which results in the junction opening [4,111]. With such 
an ability, chitosan and chitosan carriers have been frequently reported to improve the mucosal 
absorption of drugs through roughly all the routes of administration, contributing to increased 
bioavailability [21,22,87,112,113]. However, by the proper concept of permeation improvement by 
the mentioned mechanism, chitosan interferes with the normal barrier function of the epithelia. What 
makes this alteration acceptable is its non-permanent character, as the opening of tight junctions is 
known to be reversible when the contact with the polymer or the carriers is ceased [4,114–116]. An 
example of this effect is depicted in Figure 6, using chitosan/cyclodextrin nanoparticles.  
In the majority of works it is reported that the decrease of TER induced by chitosan is more 
pronounced for chitosan solutions than for chitosan carriers, which has been attributed to the fact that 
in the carriers there are less chemical groups exposed that are available for an interaction with cell 
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surfaces, as compared with the polymer chains available in solution [117,118]. However, in some 
studies it has been observed that nanoparticles produced a more accentuated decrease of TER than 
solutions [116]. One possible explanation for these different observations is the fact that the 
carriers/solutions are in contact with the cells in media of different pH. As chitosan pKa is around 6.5, 
the polymeric chains in solution or the carriers will form (or not) aggregates in dependence of the final 
pH of the medium they are incubated in. These aggregates will have different sizes, which promote 
different patterns of contact with the cells. 
Figure 6. Effect of chitosan/cyclodextrin nanoparticles (40 μg/cm2) on the TER of Calu-3 
cell monolayers at pH 6.4. Each point represents the mean ± SD (n = 5). Keys: (○) control 
HBSS pH 7.4; (Δ) control HBSS pH 6.4; (▲) chitosan/sulfobutylether-β-cyclodextrin/  
tripolyphosphate (4/3/0.25) nanoparticles; (◆ ) chitosan/carboximethyl-β-cyclodextrin/  
tripolyphosphate (4/4/0.25) nanoparticles; dotted line (----) represents the start of the 
reversibility experiment [115].  
 
If considered that TER can be used to indicate alterations of cell function, as already explained, it is 
obvious that chitosan carriers evidence that effect. However, the demonstration that the effect is 
reversible, permitting a complete recovery of the cellular function upon removal of the stressing agent, 
is also a remarkable outcome. Although these observations cannot be used to say that chitosan carriers 
are biocompatible, the reversibility of the effect on the barrier integrity makes it being acceptable.  
3.3. In Vitro Genotoxicity 
Genotoxicity assays provide an examination of the ability of chitosan carriers to damage cellular 
DNA upon contact with the cells. The most used test is called the comet assay (Table 2), which assays 
the DNA damage in individual cells using gel electrophoresis [64]. The cells are exposed to an electric 
field to attract the broken and negatively charged DNA to the anode. After that separation, a 
fluorescent dye is used to stain DNA, like propidium iodide. Afterwards, the gel is read and cells 
appear distributed as comets, with intact DNA residing in the head and broken DNA migrating to form 
the tail. The extent of the tail gives an indication on the number of DNA strand breaks [64,119]. 
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Genotoxic evaluation of chitosan carriers is not frequent and a very scarce number of works are 
available. Chitosan oligosaccharides and a low molecular weight chitosan indicated an absence of 
genotoxicity in lymphocytes [120]. In a work with chitosan-coated silver nanoparticles proposed as an 
alternative to conventional antibiotics, the comet assay revealed that a concentration of nanoparticles 
of 3 ppm does not elicit a genotoxic effect on mouse macrophages (RAW264.7 cells). In contrast, 
20 ppm of the nanoparticles induce the formation of a comet with a considerable tail [82]. 
3.4. In Vitro Monitorisation of Inflammatory Response 
The development of an inflammatory response as a result of cell contact with carriers has also been 
used as an indicator of biocompatibility. Testing this hypothesis encompasses the quantification of the 
release of various inflammatory markers, namely the cytokines IL-6, IL-8 and the tumor necrosis 
factor (TNF)-α. While IL-8 is a chemotatic agent for inflammatory cells, IL-6 is responsible for 
neutrophil activation and TNF-α is an acute inflammatory response cytokine [121]. A limited number 
of works dealing with chitosan carriers for drug delivery applications refer to this evaluation.  
PLGA-CS nanoparticles demonstrated to not induce an increase in any of these inflammation markers 
upon incubation with Calu-3 cells in nanoparticle concentrations up to 0.2 mg/mL [96]. Chitosan 
microspheres encapsulating PLGA nanoparticles generally evidenced no ability to increase TNF-α 
secretion by RAW264.7 cells (macrophages) in concentrations up to 1.6 mg/mL [28]. The same cell 
line evidenced an absence of effect on the levels of IL-6, IL-8 and TNF-α mediated by the presence of 
chitosan-DNA nanoparticles up to 24 h, even at the higher nanoparticle concentration tested  
(60 µg/mL) [122]. 
As described for other tests, the highest limitation in performing a comparison of results lies in the 
variety of conditions, in this particular case most related in the wide range of concentrations tested. 
Interestingly, from concentrations as low as 0.06 mg/mL to much higher values (1.6 mg/mL)  
the observation remained very similar and reported no ability of the tested carriers to induce 
inflammatory responses. 
3.5. In Vivo Studies 
In vivo studies are essential for the final establishment of biocompatibility. Even when assuming 
that in vitro cell studies reflect the in vivo observations considering the same cells, it cannot be 
forgotten that in cell cultures only a few of the in vivo variables are accounted for, thereby not 
permitting a real simulation of the in vivo environment. In addition, cell cultures are very sensitive to 
environmental changes, such as temperature, pH and nutrient concentrations, demanding a 
confirmation of observations in an in vivo setting [64]. As critically pointed out in a recent review 
addressing the biocompatibility of drug delivery systems, a carrier may not cause any tissue injury at 
all, but kill an animal either from drug release or from problems related with intravascular coagulation, 
embolic events, chelation of ions vital to homeostasis, etc. [57]. This actually means that, although not 
directly cytotoxic, the carrier (as any material) can induce a destructive reaction thereafter [57], which 
makes in vivo assays mandatory and determinant after a certain moment and, definitely, well before 
any attempt of claiming for a human application of the developed carrier. This ambitious step needs to 
be accounted for regarding both the carrier effectiveness and safety. 
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Chitosan biodegradability represents a step forward concerning safety requirements, as it prevents 
its accumulation in the organism. As mentioned in Section 2, chitosan of suitable molecular weight is 
said to be directly cleared by the kidney, while that of excessive molecular weight is first degraded into 
fragments that undergo renal clearance afterwards [11,21]. As previously observed in some in vitro 
tests, chitosan carriers present a decreased toxicity profile as compared with the corresponding 
polymeric solutions, because the interaction pattern with cellular structures is different between free 
polymeric chains and the carriers. The same observation applies, in some cases, to the comparison 
between loaded and unloaded chitosan carriers. In fact, the loading of a carrier with a drug might cause 
surface alterations on the carrier, for instance at the level of its surface charge. Some works report that 
drug loading produces a charge decrease, thereby modifying the interactions with cells and the 
microenvironment, often leading to decreased toxicity [16]. However, the previous observation that 
drug release by itself can cause acute toxicity, depending on the release pattern, cannot be disregarded. 
There are mainly two different in vivo studies that have been used to assess the biocompatibility of 
chitosan carriers. By one side it is important to observe histopathological effects resulting from the 
contact with the carrier. In turn, it is also relevant to determine the inflammatory response induced by 
the carrier, which is monitored by the determination of several pro-inflammatory cytokines. 
Additionally, the appearance of relevant alterations in normal clinical signs (diarrhea, fever or other 
systemic symptoms) is frequently monitored. In what concerns the evaluation of chitosan carriers, 
there is a high incidence in the assessment of both the oral and the pulmonary routes, but others have 
also been approached. 
The LD50 of paclitaxel-loaded chitosan micelles administered intravenously to mice was 72.16 mg/kg. 
Moreover, intravenous administration to rabbits did not induce histophatological effects at a dose of 6 
mg/kg/day during 3 days [123].  
For the administration of carriers through the lung route, several different observations were 
performed using different particles. Chitosan-graft-spermine/pDNA nanoparticles administered to mice 
using a nose-only device revealed an absence of detectable damage. The histopathological evaluation 
of the lungs evidenced absence of necrosis, metaplasia, anaplasia in pneumocytes, atelectasis or 
emphysema. Capillary vessels within the alveolar wall were not enlarged and damaged endothelial 
cells were rarely observed. Neither congestion nor hemorrhage was noticeable, along with an absence 
of infiltration of inflammatory cells. In addition, abnormal features were not detected in other major 
organs (brain, heart, lung, liver, kidney and spleen) [124]. In contrast, the intratracheal administration 
of glycol chitosan/cholanic acid nanoparticles to mice (2 mg/kg) induced mild inflammation. Transient 
neutrophilic pulmonary inflammation was observed from 6 h to 3 days after administration and the 
lung expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), as well as that of the 
chemokine MIP-1α, increased during the first 24 h, recovering to normal levels thereafter [125]. A 
more pronounced inflammatory effect was detected upon intratracheal administration to rats of 
unloaded chitosan microparticles (2–10 mg/kg of particles). A dose-dependent pro-inflammatory effect 
was manifested by increased levels of bronchoalveolar lavage fluid protein, lactate dehydrogenease 
activity and increases in lung tissue myeloperoxidase activity and leukocyte migration. A cytological 
examination of bronchoalveolar fluid further evidenced a large infiltration of neutrophils, which are 
inflammatory cells [126]. Unfortunately, the authors did not include any group of animals examined 
sometime after the inhalations, to verify whether a recovery from the inflammation occurred. 
J. Funct. Biomater. 2012, 3     
 
 
631
It is also noticeable that in the latter work the used dose varied from 2 to 10 mg/kg, while the 
previous one only assessed a dose of 2 mg/kg. Obviously the different composition of the particles in 
both works has a great impact on the observed response, apart from the fact that the former work 
assesses nanoparticles, while the latter tests microparticles. However, it is important to mention that 
chitosan microparticles administered at the dose of 2 mg/kg induced a response similar to that of the 
control in practically all the assayed parameters [126], thus being considered to not induce an 
inflammatory response. When comparing both systems assessed at the same concentration (2 mg/kg), a 
similar absence of inflammatory effect was determined. 
For the oral administration varied responses were also reported. An evaluation of the hepatotoxicity 
of 3 doses (125 mg/kg each dose) of unloaded alginate/chitosan microparticles administered to 
guinea pigs spaced by 10 days, revealed no toxic effect by measurement of the indicators of liver 
function serum bilirubin, alanine aminotransferase and alkaline phosphatase [127]. Unloaded 
chitosan/poly-γ-glutamic acid nanoparticles were reported to not induce significant toxicity upon oral 
administration of a daily dose of 100 mg/kg for 14 days. As compared to untreated animals, there was 
no evidence of different clinical signs. In addition, no pathological changes in liver, kidney and 
intestinal segments were observed [128]. The ability of these nanoparticles to induce hepatotoxicity 
was also verified by monitoring alanine aminotransferase and aspartate aminotransferase. No alteration 
in the parameters was obtained after the administration, nor was a histological effect observed [129]. 
Trimethyl chitosan oligomer/DNA nanoparticles administered orally twice a week during 4 weeks, 
caused slight diarrhea at 3 weeks in animals treated with 0.5 mg/mL of nanoparticles (containing 
0.1 mg/mL DNA), which was relieved upon stopping the administration [130]. This was considered 
very mild toxicity.  
A very small increase of serum cytokine levels (IL-2, IL-6, IL-12, TNF-α) was observed upon 
administration of chitosan and polyethylenelglycol-coated PLGA nanoparticles (20 mg/mL) to mice, 
which completely recovered to normality at 6 h [131]. Chitosan reduced gold nanoparticles demonstrated 
a very high LD50 (greater than 2000 mg/kg) after administration to rats for a 28 day period. No 
significant changes were detected in clinical signs, body weight, food consumption, hematological 
parameters, organ weights or histopathological aspects [132]. 
Although occasionally some augmented inflammatory response has been reported, the general trend 
seems to be that no important toxicity or only minimal toxic effects are generated by the administration 
of chitosan-based carriers. This might be a significant indicator of chitosan safety, but ascertaining the 
specific conditions to be established in each administration modality and, somehow, provide a 
standardization of the procedures, remains the most important issue.  
4. Conclusions and Expert Opinion 
Biocompatibility is not a simple interaction between one material and one cell type, but may instead 
involve degradation products, separate effects from drug and carrier, as well as numerous cell types 
that present themselves at different times. Therefore, mitigating problems with biocompatibility is 
rather challenging as, apart from the material properties, poorly understood drug- and material-tissue 
interactions are also involved. Carriers are also becoming increasingly complex, composed of multiple 
materials, demanding the need to find components that may yield any toxic influence on the carrier as 
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a whole. In turn, as immune reactions are so complex and individual, the biocompatibility of a carrier 
cannot be adequately described only by taking into account a single type of cell or tissue.  
The most common assays testing biocompatibility of chitosan carriers are in vitro cytotoxicity 
assays, which are usually performed for short periods, rarely going beyond 96 h and in most cases 
remaining in the 12–24 h or even less. As a result, these assays only measure finite effects on cells 
during the first hours after exposure to toxic substances. After contact with a toxic or stressing agent, 
the cells either recover from, or succumb to, the induced injury. Therefore, in addition to the typical 
protocol of cytotoxicity evaluation that includes cell incubation with the carrier and an immediate 
measurement of the parameter being tested, it would be useful to remove the carrier and permit cell 
incubation with culture medium for a certain period, for instance 24 or 48 h, before performing the 
cytotoxic evaluation. The ISO 10993 [61–63] gives a good indication of the type of tests that should be 
considered initially, indicating that an early test of carrier toxicity might avoid expensive and 
undesirable development work. However, the assertive evaluation of toxicity will only be possible 
when standard conditions are implemented, so that all reported results converge from well-defined 
assay settings. In this way, comparing the panoply of results would be a much more accurate and 
facilitated process and higher benefit would be taken from the produced data.  
Another important aspect is that most of the conducted studies are performed in immortalized cell 
lines but, at least after obtaining satisfactory toxicity profiles, it would be important to repeat those 
studies in primary cell cultures, as these closely resemble the in vivo environment and are, therefore, 
more realistic [133]. Different sensitivity has been observed between primary and established cell  
lines [37,38] and, although primary cell cultures are more difficult to establish, they register variability 
among different donors, which will contribute to the similarity of in vivo situations, where  
inter-individual variability is also observed. In summary, the in vitro studies of biocompatibility should 
assess both the carrier and the drug and, when necessary, the individual components of the carrier. 
Furthermore, different cells lines, as well as primary cell cultures, should be used with adequate time 
periods and likewise incubation/recovery protocols, tested.  
Notwithstanding the importance of in vitro testing at the initial stage of evaluation of a determined 
carrier, it is known that the resulting findings frequently lack predictive value of in vivo occurrences. 
In vivo assays therefore become essential. As mentioned for the in vitro studies in cell culture, a wide 
variety of assay conditions is also observed in in vivo tests. This disparity focuses not only the 
performed tests, but also the protocols of each test. Some authors assess the loaded carriers, while 
others test unloaded particles. Different media are used to suspend the particles, when applicable. 
Some authors monitor the animals for a certain period after the last administration, in order to assess 
the reestablishment of normal functions; while others do not assess this possibility. Therefore, once 
again a standardization of procedures would be helpful and essential to allow advancements in the 
evaluation of chitosan carriers. 
As previously mentioned, chitosan is available in a wide range of different characteristics 
(molecular weight, deacetylation degree, several different chemical derivatives). It must be, then, 
recalled that different polymeric characteristics might result in structurally different carriers and, 
consequently, in diverse responses in vitro and in vivo. Therefore, different carriers and raw materials 
should be tested accordingly. Considering the available literature on the subject as a whole, chitosan 
carriers have generally demonstrated to not exhibit overt toxicity, but actually neither nanoparticles nor 
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microparticles can be seen as inert. Microparticles are generally taken up by macrophagic cells very 
easily, thus having the potential to initiate an inflammatory reaction. In turn, the biological 
consequences of nanoparticle interactions are not well understood so far, but they should be addressed 
cautiously, considering their ability to gain a size-dependent access to intracellular compartments [57]. 
Nevertheless, it is interesting to observe, for instance, that chitosan microparticles (around 150 µm) 
received approval as a support for the growing of fibroblasts [134], an observation that reinforces 
evidence of chitosan potential. 
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